You are here: Industry Insights > Market News > Lupin launches Mycophenolate Mofetil Tablets USP

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Lupin launches Mycophenolate Mofetil Tablets USP

expresspharmaDecember 30, 2020

Tag: lupin , Mycophenolate Mofetil tablets , ANDA

Favorites

Lupin announced the launch of Mycophenolate Mofetil Tablets USP, 500 mg, after Lupin’s alliance partner Concord Biotech received approval for its ANDA from the United States Food and Drug Administration.

Mycophenolate Mofetil Tablets USP, 500 mg, are the generic equivalent of CellCept Tablets of Roche Palo Alto, indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.

Mycophenolate Mofetil Tablets USP (RLD: CellCept) had an annual sales of approximately $87 million in the US. (IQVIA MAT October 2020).

Previous:Glenmark launches Remogliflozin + Vildagliptin FDC in India to treat Type 2 diabetes

Next:AstraZeneca and Oxford-made Covid-19 vaccine not ready for EU market approval

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Lupin launches Mycophenolate Mofetil Tablets USP | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Standard tracheostomy tube

FDF standard butterfly valve

hualan bio Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Standard HVAC System Toiletry/ ICU/ Pharmaceutical/ Hospital/ Medical/ Lab/ Electronics/ Food Cleanr

High standard and safety Human Coagulation Factor VIII without preservatives and antibiotics

Automatic standard repeated injection pen/Disposable injection pen (automatic injection)

Clean Room Manufacturer GMP Standard Modular Turnkey Cleanroom Project Supplier for Medical Hospital

Standard endotracheal tube

Rutin NF11 (USP 32 Standard)

terbinafine hydrochloride In-house standard

Lupin launches Mycophenolate Mofetil Tablets USP

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>